6th Annual Pharma Packaging and Labeling USA 201426-27 February 2014, Philadelphia, USA
The 6th year of a truly successful and respected Pharma Packaging and Labeling event is rolling back into town with this year expected to be bigger than ever.
With key legislation on the horizon in California and the counterfeiting market now worth millions of dollars as well as sustainability and green packaging in demand, the need for this event is heightened.
We aim to bring you more compelling speakers talking about the subjects that matter to you. Following extensive research into the market we have been able identify key themes to discuss, issues to debate and people you want to meet all under one roof.
This outstanding event will provide a fantastic opportunity for exhibitors to promote their products and services to senior level decision makers from the region. Exhibition spaces are filling up due to the success of last year’s event as well as the global reputation of this world-renowned series.
Pharma Packaging and Labeling 2014 aims to target specific areas of the market in an interesting and insightful manner.
Rondo Pak would like to welcome all attendees of Pharma Packaging and Labeling to their drink reception taking place at the end of day one, on the 26th of February.
Denmark-based Novo Nordisk has introduced Ryzodeg (insulin degludec/insulin aspart) in Mexico, which will be used to treat adult patients suffering from type 2 diabetes.
The US Food and Drug Administration (FDA) has cleared a supplemental new drug application (sNDA) for UCB’s Vimpat (lacosamide) C-V as montherapy to treat partial-onset seizures in patients with epilepsy.
Pfizer and Protalix BioTherapeutics have secured approval from the US Food and Drug Administration (FDA) for Elelyso (taliglucerase alfa) to treat paediatric patients with type 1 Gaucher disease.
US-based BioCryst Pharmaceuticals has received an additional $2.4m funding from the National Institute of Allergy and Infectious Diseases (NIAID) to carry dose ranging efficacy study of an intramuscular formulation of BCX4430 in non-human primates to…
The UK Government is set to add an additional £160m to the Cancer Drugs Fund, in order to improve treatment for patients.